LipiDiDiet trial, post-hoc analyses of the 3-year data published

Nutricia welcomes the publication in The Journal of Prevention of Alzheimer's Disease of post-hoc analyses of 3-year data from the LipiDiDiet trial, a multinutrient intervention in prodromal Alzheimer’s disease1.

The LipiDiDiet randomized controlled trial evaluated the long-term effects of Fortasyn Connect (Souvenaid) compared with control in participants with mild cognitive impairment due to Alzheimer’s Disease / prodromal AD1,3. A number of post-hoc analyses based on 36-month data have now been updated and published in the Journal of Prevention of Alzheimer’s disease (JPAD).

The study, entitled “Combined evidence for a long-term, clinical slowing effect of multinutrient intervention in prodromal Alzheimer’s disease: post-hoc analysis of 3-year data from the LipiDiDiet trial” reports statistically significant results of 3 different post-hoc analyses on evaluating the totality of evidence (ADCOMS, a global statistical test (GST) and Bayesian hierarchical modelling (BHM)) in the LipiDiDiet 3-year dataset.

Previously, researchers reported a post-hoc analysis of 24-month data from the LipiDiDiet trial using the Alzheimer’s Disease Composite Score (ADCOMS), a composite tool and more sensitive measure of intervention effects than the Neuropsychological Test Battery (NTB) used in the primary analysis of the trial4,5The results from the new publication showed that the difference in ADCOMS observed over 24 months was sustained over 36 months (36% less worsening in active vs. control at both time points). In addition, also the two other tests evaluating the totality of evidence showed a statistically significant effect for the intervention, which is consistent with an overall effect of the specific multinutrient intervention on AD progression over 36 months2.

Multinutrient intervention can be considered as part of an overall strategy to encourage healthy lifestyle and improve diet in people at risk of progression to AD dementia. This post-hoc analysis showed that participants taking Souvenaid showed significantly less clinical decline over 36 months as measured by ADCOMS, suggesting long-lasting beneficial effects of the multinutrient in a prodromal AD/pre-dementia population with MCI.

  2. Soininen H, Solomon A, Visser PJ, Hendrix SB, Blennow K, Kivipelto M, et al. 36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease. Alzheimers Dement. 2021;17:29-40. 10.1002/alz.12172
  3. Baumel BS, Doraiswamy PM, Sabbagh M, Wurtman R. Potential Neuroregenerative and Neuroprotective Effects of Uridine/Choline-Enriched Multinutrient Dietary Intervention for Mild 17 Cognitive Impairment: A Narrative Review. Neurology and therapy. 2021;10:43-60. 10.1007/s40120-020-00227-y
  4. Soininen H, Solomon A, Visser PJ, Hendrix SB, Blennow K, Kivipelto M, et al. 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurol. 2017;16:965-975. 10.1016/S1474- 4422(17)30332-0
  5. Hendrix SB, Soininen H, van Hees AMJ, Ellison N, Visser PJ, Solomon A, et al. Alzheimer's Disease Composite Score: A Post-Hoc Analysis Using Data from the LipiDiDiet Trial in Prodromal Alzheimer's Disease. The journal of prevention of Alzheimer's disease. 2019;6:232-236. 10.14283/jpad.2019.33

Are you a healthcare professional or (carer of) a diagnosed patient?

The product information for this area of specialization is intended for healthcare professionals or (carers of) diagnosed patients only, as these products are for use under healthcare professional supervision.

Please click ‘Yes’ if you are a healthcare professional or (carer of) a diagnosed patient, or ‘No’ to be taken to a full list of our products.

The information on this page is intended for healthcare professionals only.

If you aren't a healthcare professional, you can visit the page with general information, by clicking 'I'm not a healthcare professional' below.